We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Detection Rate of Monoclonal Gammopathy of Undetermined Significance Determined

By LabMedica International staff writers
Posted on 30 Jun 2020
Multiple myeloma (MM) is a clonal plasma cell malignancy that accounts for approximately 2% of all malignancies. More...
Plasma cells help you fight infections by making antibodies that recognize and attack pathogens. Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they displace healthy blood cells.

Monoclonal gammopathy of undetermined significance (MGUS) is characterized by the presence of monoclonal protein (M-protein) lower than 30 g/L, the presence of fewer than 10% plasma cells in the bone-marrow and the absence of end-organ damage such as hypercalcemia, renal insufficiency and bone lesion.

At the Worcester Royal Hospital (Worcester, UK) a total 9,636 protein electrophoresis was carried out, of these approximately 55% were reflex tested based on abnormal serum globulin levels. Protein electrophoresis and immunofixation was carried out in 2006 using the Hydragel (Sebia UK, Camberley, UK). In 2011 the analytical method for detection, typing and quantitation of monoclonal protein (M-protein) was changed to capillary electrophoresis and immunosubtraction using the Sebia Capillarys technology. Total protein was measured using the biuret method and albumin using the bromocresol green method (Roche Diagnostics, Burgess Hill, UK). MGUS diagnosis was based on M-protein value, complete blood count, renal function and bone profile (calcium, phosphate, albumin and alkaline phosphatase in serum).

Kaplan–Meier analysis of patients with an M-protein showed that lymphoplasma-cell proliferative disorders (LPD)-free survival was 91% for both 10 year and more than 10 year follow-up. LPD-free survival decreased to approximately 73% when competing causes (death due to unrelated causes, transient M-protein, loss to follow-up) were censored. Progression to LPD occurred at initial M-protein values of 3g/L at diagnosis. During follow-up, 38.3% died without evidence of LPD, 12% were diagnosed with transient M-protein, 8.7% developed LPD, 10.9% had stable M-protein, 4.9% showed increasing M-protein, and 25.2% were lost to follow-up. Survival curves showed that M-protein isotype contributed to LPD-free survival in the order IgG=IgM>IgA>biclonal M-protein.

The inference from the study was that the risk of transformation to LPD did not diminish even after 10 years. If competing factors were taken into account, approximately one in four of the patients followed over a period of 10 years or longer was at risk of developing a lymphoid malignancy. The study was published on May 14, 2020 in the Journal of Blood Medicine.



New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Drug Test Kit
DrugCheck 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.